BRCA1 antibody | knockout validation | Abcam ab191042
DOI
//dx.doi.org/10.13070/ko.en.7.2161
Date
2017-03-16

This is a knockout-validated antibody summary, based on the publication "Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

BRCA1 antibody | knockout validation | Abcam ab191042 figure 1
Figure 1. Western blot analysis of proteins extracted from control fibroblasts (empty vector transfected) and BRCA1-KO fibroblasts. β-Actin serves as loading control. Note that BRCA1 signal is absent in BRCA1-KO fibroblasts. (*) points to the BRCA1 signal. From [1].
Antibody information

Rabbit polyclonal IgG

Company: Abcam

Antibody: BRCA1

Catalog number: ab191042

Summary: Rabbit polyclonal IgG against a recombinant fragment corresponding to human BRCA1 aa 1,661-1,863 (C terminal). Reacts with human, mouse and rat. Suitable for western blot and immunohistochemistry (paraffin). Predicted to work with dog, chimpanzee, Rhesus monkey, and gorilla.

Validation Method

Western blot

Sample

Control (empty vector transfected) and BRCA1-KO human fibroblasts. Cells were lysed in RIPA buffer containing protease inhibitors (Sigma, Oakville, Canada).

Blocking agent

TBS containing 5 % non-fat dry milk.

Primary incubation

Overnight at 4 °C.

Secondary incubation

Anti-rabbit peroxidase-conjugated secondary antibody for 1 h at room temperature.

Detection

Immobilon Western HRP Substrate (Millipore, Etobicoke, Canada).

References
  1. Hamam D, Abdouh M, Gao Z, Arena V, Arena M, Arena G. Transfer of malignant trait to BRCA1 deficient human fibroblasts following exposure to serum of cancer patients. J Exp Clin Cancer Res. 2016;35:80 pubmed publisher